Clinical Trial: MK0524A Phase IIb Study (0524A-011)(COMPLETED)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Part A: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of MK0524 Compared to Placebo Part B: A Dose-Ranging Study to Evaluate the Tolerability of MK0524 and Its Effects on

Brief Summary:

Part A: This study will determine that MK0524 is well tolerated and does not effect lipids and blood glucose when given alone.

Part B: Determine dose ranges for MK0524 and MK0524 plus Niaspan(R) on the effects of lipids and blood glucose.

Detailed Summary:
Sponsor: Merck Sharp & Dohme Corp.

Current Primary Outcome: To determine the effect of MK0524A on lipids and blood glucose [ Time Frame: 17 Weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome: To establish the dose for limiting flushing symptoms induced by NIASPAN (R) [ Time Frame: 17 Weeks ]

Original Secondary Outcome: Same as current

Information By: Merck Sharp & Dohme Corp.

Dates:
Date Received: September 26, 2007
Date Started: August 2004
Date Completion:
Last Updated: August 24, 2015
Last Verified: August 2015